drugset / Trial / NCT01358253
Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to evaluate the safety and efficacy of Rituximab combined with chemotherapy in CD20+ adult acute lymphoblastic leukemia.
Timeline
- Start
- 2010-12
- Primary completion
- 2012-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | Intravenous |
| Background | Cytarabine | Small molecule | 2 g | Intravenous |
| Background | Dexamethasone | Small molecule | 40 mg | Intravenous |
| Background | Doxorubicin | Other / unclassified | 50 mg/m2 | Intravenous |
| Background | MERCAPTOPURINE ANHYDROUS | Small molecule | 60 mg/m2 | — |
| Background | Methotrexate | Small molecule | 25 mg/m2 | Intravenous |
| Background | Prednisone | Other / unclassified | 40 mg/m2 | — |
| Background | Vincristine | Small molecule | 1.4 mg/m2 | Intravenous |
| Background | asparaginase | Protein / enzyme biologic | 6000 unknown | Intravenous |